Drug | AUCT | AUCI | Cmax |
---|---|---|---|
Amlodipine | MSR 0.021, CV 14.6% | MSR 0.020, CV 14.2% | MSR 0.027, CV 16.5% |
 Generic a vs Reference (54) | 98.24% (93.76–102.94) | 97.84% (93.48–102.41) | 96.735% (91.75–102.00) |
 Generic b vs Reference (54) | 96.61% (92.20–101.23) | 95.83% (91.56–100.30) | 94.578% (89.699–99.72) |
 Generic c vs Reference (53) | 98.95% (94.39–103.72) | 98.14% (93.72–102.76) | 94.569% (89.645–99.76) |
 Generic a vs Generic b (55) | 102.34% (97.71–107.19) | 102.70% (98.16–107.47) | 101.71% (96.51–107.19) |
 Generic b vs Generic c (54) | 96.90% (92.56–101.63) | 97.11% (92.78–101.64) | 99.84% (94.69–105.27) |
 Generic a vs Generic c (54) | 99.25% (94.72–104.00) | 99.76% (95.31–104.41) | 101.498% (96.26–107.02) |
Amoxicillin | MSR 0.012, CV 11.0% | MSR 0.011, CV 10.5% | MSR 0.037, CV 19.4% |
 Generic a vs Reference (49) | 100.68% (97.01–104.49) | 100.48% (96.97–104.12) | 98.87% (92.63–105.53) |
 Generic b vs Reference (49) | 107.45% (103.53–111.52) | 106.92% (103.19–110.79) | 109.20% (102.30–116.55) |
 Generic c vs Reference (49) | 104.99% (101.16–108.96) | 104.78% (101.12–108.58) | 111.32% (104.29–118.82) |
 Generic a vs Generic b (49) | 93.98% (90.70–97.38) | 93.95% (90.67–97.35) | 90.54% (84.83–96.65) |
 Generic b vs Generic c (49) | 101.04% (98.48–105.73) | 101.93% (98.36–105.62) | 98.10% (91.90–104.71) |
 Generic a vs Generic c (49) | 95.89% (92.55–99.37) | 95.76% (92.41–99.23) | 88.82% (83.21–94.80) |
Atenolol | MSR 0.037, CV 19.4% | MSR 0.036, CV19.2% | MSR 0.055, CV 23.8% |
 Generic a vs Reference (48) | 105.84% (99.08–113.05) | 105.52% (98.88–112.61) | 106.46% (98.24–115.37) |
 Generic b vs Reference (48) | 103.12% (96.54–110.14) | 102.71% (96.25–109.61) | 103.10% (95.14–111.73) |
 Generic c vs Reference (48) | 111.87% (104.73–119.49) | 111.41% (104.41–118.90) | 106.58% (98.35–115.49) |
 Generic a vs Generic b (48) | 102.64% (96.09–109.63) | 102.74% (96.27–109.64) | 103.26% (95.29–111.90) |
 Generic b vs Generic c (48) | 92.18% (86.30–98.46) | 92.19% (86.39–98.38) | 96.74% (89.27–104.84) |
 Generic a vs Generic c (48) | 94.61% (88.58–101.06) | 94.71% (88.75–101.08) | 99.89% (92.18–108.25) |
Cephalexin | MSR 0.008, CV 8.9% | MSR 0.008, CV 8.9% | MSR 0.040, CV 20.3% |
 Generic a vs Reference (32) | 99.46% (95.77–103.29) | 95.50% (92.98–99.16) | 107.53% (98.73–117.10) |
 Generic b vs Reference (32) | 101.43% (97.67–105.34) | 101.18% (97.45–105.06) | 95.11% (87.33–103.58) |
 Generic c vs Reference (32) | 98.65% (94.99–102.41) | 98.44% (94.81–102.21) | 105.52% (96.89–114.92) |
 Generic a vs Generic b (32) | 94.39% (90.91–98.00) | 94.36% (90.88–97.97) | 113.06% (103.81–123.13) |
 Generic b vs Generic c (32) | 102.79% (99.99–106.72) | 102.86% (99.07–106.80) | 90.13% (82.76–98.16) |
 Generic a vs Generic c (32) | 97.02% (93.44–100.73) | 97.06% (93.48–100.77) | 101.90% (93.57–110.98) |
Ciprofloxacin | MSR 0.012, CV11.0% | MSR 0.012, CV 11.0% | MSR 0.020, CV14.2% |
 Generic a vs Reference (41) | 93.40% (89.67–97.29) | 92.99% (89.28–96.86) | 94.20% (89.37–99.29) |
 Generic b vs Reference (41) | 98.38% (94.45–102.47) | 97.51% (93.62–101.57) | 92.92% (88.15–97.94) |
 Generic c vs Reference (41) | 101.77% (97.71–106.01) | 101.37% (97.32–105.59) | 103.39% (98.09–108.98) |
 Generic a vs Generic b (41) | 94.94% (91.15–98.89) | 95.36% (91.55–99.33) | 101.38% (96.18–106.86) |
 Generic b vs Generic c (42) | 91.78% (88.11–95.60) | 91.74% (88.07–95.55) | 91.11% (86.44–96.04) |
 Generic a vs Generic c (41) | 96.83% (93.01–100.81) | 96.39% (92.59–100.35) | 90.16% (85.60–94.97) |
Clarithromycin | MSR 0.060, CV 24.9% | MSR 0.057, CV 24.2% | MSR 0.100, CV 32.4% |
 Generic a vs Reference (48) | 96.40% (88.64–104.85) | 96.91% (89.30–105.17) | 93.85% (84.22–104.60) |
 Generic b vs Reference (47) | 102.52% (94.18–111.60) | 103.61% (95.39–112.54) | 96.28% (86.29–107.42) |
 Generic c vs Reference (48) | 89.22% (82.04–97.04) | 89.83% (82.77–97.49) | 87.74% (78.73–97.78) |
 Generic a vs Generic b (47) | 93.97% (86.32–102.29) | 93.42% (86.01–101.48) | 96.98% (86.92–108.21) |
 Generic b vs Generic c (47) | 115.23% (105.85–125.43) | 115.70% (106.51–125.68) | 109.97% (98.56–122.70) |
 Generic a vs Generic c (48) | 108.05% (99.35–117.51) | 107.88% (88.41–117.08) | 106.97% (95.98–119.21) |
Diclofenac | MSR 0.023, CV 15.3% | MSR 0.022, CV 14.7% | MSR 0.129, CV 37.1% |
 Generic a vs Reference (67) | 100.03% (95.74–104.52) | 100.19% (96.04–104.52) | 86.61% (78.08–96.08) |
 Generic b vs Reference (68) | 99.80% (95.54–104.24) | 99.77% (95.68–104.05) | 92.48% (83.43–102.51) |
 Generic c vs Reference (68) | 103.74% (99.32–108.36) | 104.01% (99.74–108.47) | 86.46% (78.00–95.83) |
 Generic a vs Generic b (68) | 101.38% (97.06–105.89) | 101.50% (97.33–105.85) | 95.64% (86.28–106.01) |
 Generic b vs Generic c (69) | 96.38%(92.30–100.64) | 96.06% (92.14–100.14) | 107.01% (96.61–118.52) |
 Generic a vs Generic c (68) | 96.71% (92.59–101.01) | 96.56% (92.59–100.70) | 100.79% (90.93–111.72) |
Ibuprofen | MSR 0.012, CV 10.9% | MSR 0.008, CV 9.1% | MSR 0.026, CV 16.3% |
 Generic a vs Reference (27) | 106.31%(101.06–111.83) | 104.65% (100.30–109.19) | 101.67% (94.30–109.62) |
 Generic b vs Reference (25) | 105.48% (100.05–111.20) | 102.94% (98.48–107.59) | 113.00% (104.47–122.23) |
 Generic c vs Reference (26) | 106.30% (100.95–111.94) | 105.69% (101.21–110.36) | 89.11% (82.52–96.22) |
 Generic a vs Generic b (26) | 102.27% (97.11–107.69) | 103.13% (98.76–107.69) | 92.17% (85.36–99.53) |
 Generic b vs Generic c (26) | 98.38% (93.418–103.60) | 96.53% (92.44–100.80) | 126.47% (117.11–136.57) |
 Generic a vs Generic c (27) | 99.87% (94.94–105.06) | 98.87% (94.78–103.16) | 114.12% (105.85–123.04) |
Fluconazole | MSR 0.004, CV 6.3% | MSR 0.004, CV 6.3% | MSR 0.006, CV 7.8% |
 Generic a vs Reference (26) | 101.33% (98.34–104.42) | 102.23% (99.21–105.35) | 106.99% (103.13–110.99) |
 Generic b vs Reference (25) | 101.06% (98.01–104.21) | 101.39% (98.33–104.55) | 109.79% (105.75–113.99) |
 Generic c vs Reference (25) | 105.66% (102.47–108.94) | 106.07% (102.86–109.36) | 109.00% (104.98–113.17) |
 Generic a vs Generic b (25) | 100.38% (97.35–103.50) | 100.39% (97.36–103.52) | 97.59% (93.99–101.32) |
 Generic b vs Generic c (25) | 95.65% (92.77–98.63) | 96.21% (93.31–99.21) | 100.73% (97.01–104.58) |
 Generic a vs Generic c (25) | 96.01% (93.12–99.00) | 96.59% (93.68–99.60) | 98.30% (94.67–102.06) |
Metformin | MSR 0.019, CV 13.8% | MSR 0.019, CV 13.8% | MSR 0.027, CV 16.5% |
 Generic a vs Reference (48) | 93.19% (88.89–97.69) | 92.44% (88.17–96.91) | 93.05% (87.96–98.44) |
 Generic b vs Reference (48) | 97.70% (93.19–102.42) | 97.31% (92.82–102.01) | 98.45% (93.06–104.15) |
 Generic c vs Reference (49) | 96.06% (91.68–100.66) | 95.51% (91.15–100.08) | 95.07% (89.92–100.52) |
 Generic a vs Generic b (49) | 100.80% (97.76–103.94) | 95.06% (90.72–99.61) | 94.41% (89.298–99.82) |
 Generic b vs Generic c (49) | 95.60% (92.71–98.57) | 102.25% (97.61–107.17) | 104.15% (98.50–110.11) |
 Generic a vs Generic c (49) | 96.36% (93.46–99.36) | 97.23% (92.79–101.88) | 98.33% (93.00–103.96) |
Metronidazole | MSR 0.003, CV 5.5% | MSR 0.003, CV 5.5% | MSR 0.010, CV 10.0% |
 Generic a vs Reference (28) | 108.73% (106.05–111.48) | 108.96% (106.28–111.72) | 109.47% (104.60–114.58) |
 Generic b vs Reference (27) | 99.569% (97.07–102.14) | 99.82% (97.31–102.39) | 97.60% (93.17–102.24) |
 Generic c vs Reference (28) | 97.439% (95.04–99.90) | 97.46% (95.06–99.92) | 100.53% (96.05–105.22) |
 Generic a vs Generic b (27) | 109.349% (106.60–112.17) | 109.32% (106.57–112.14) | 111.57% (106.50–116.88) |
 Generic b vs Generic c (27) | 102.05% (99.49–104.68) | 102.29% (99.72–104.93) | 96.95% (92.55–101.56) |
 Generic a vs Generic c (28) | 111.59% (108.84–114.41) | 111.81% (109.05–114.63) | 108.90% (104.05–113.98) |
Omeprazole | MSR 0.035, CV 18.9% | MSR 0.035, CV 18.9% | MSR 0.066, CV 26.1% |
 Generic a vs Reference (74) | 97.49% (92.62–102.62) | 97.44% (92.57–102.56) | 90.57% (84.41–97.17) |
 Generic b vs Reference (73) | 96.21% (91.37–101.30) | 97.05% (92.17–102.19) | 84.85% (79.04–91.08) |
 Generic c vs Reference (74) | 98.14% (93.24–103.30) | 98.09% (93.19–103.25) | 87.82% (81.85–94.23) |
 Generic a vs Generic b (73) | 101.33% (96.24–106.70) | 100.34% (95.30–105.66) | 106.59% (99.30–114.4) |
 Generic b vs Generic c (74) | 97.59% (92.71–102.72) | 98.55% (93.63–103.73) | 96.35% (89.80–103.37) |
 Generic a vs Generic c (74) | 99.34% (94.38–104.56) | 99.33% (94.37–104.55) | 103.13% (96.12–110.64) |
Paracetamol | MSR 0.008, CV 8.8% | MSR 0.008, CV 9.1% | MSR 0.031, CV 17.6% |
 Generic a vs Reference (40) | 91.57% (88.62–94.62) | 91.81% (88.76–94.96) | 104.99% (98.30–112.14) |
 Generic b vs Reference (38) | 99.69% (96.35–103.14) | 99.66% (96.22–103.22) | 103.48% (96.71–110.73%) |
 Generic c vs Reference (39) | 97.95% (94.71–101.29) | 97.86% (94.53–101.30) | 101.17% (94.63–108.15) |
 Generic a vs Generic b (38) | 100.01% (96.71–103.43) | 100.26% (96.85–103.79) | 101.76% (95.18–108.78) |
 Generic b vs Generic c (38) | 94.29% (91.18–97.52) | 94.29% (91.09–97.62) | 102.27% (95.57–109.43) |
 Generic a vs Generic c (39) | 102.11% (98.74–105.60) | 102.46% (98.97–106.07) | 104.11%(97.38–111.30) |
Ranitidine | MSR 0.021, CV 14.6% | MSR 0.020, CV 14.2% | MSR 0.047, CV 21.9% |
 Generic a vs Reference (70) | 102.68% (98.57–106.96) | 102.43% (98.43–106.59) | 105.26% (99.02–111.89) |
 Generic b vs Reference (71) | 102.54% (98.47–106.79) | 102.50% (98.52–106.64) | 98.21% (92.43–104.34) |
 Generic c vs Reference (72) | 101.84% (97.82–106.02) | 101.81% (97.89–105.89) | 104.51% (98.40–111.00) |
 Generic a vs Generic b (70) | 100.30% (96.38–104.37) | 100.29% (96.37–104.37) | 107.89% (101.49–114.69) |
 Generic b vs Generic c (71) | 100.27% (96.38–104.31) | 100.34% (96.45–104.39) | 93.64% (88.13–99.49) |
 Generic a vs Generic c (70) | 100.30% (96.38–104.38) | 100.38% (96.45–104.46) | 100.66% (94.70–107.01) |